-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Bellicum Pharmaceuticals, Inc quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from 2015 to 2022.
- Bellicum Pharmaceuticals, Inc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending September 30, 2023 was -$763K, a 89.4% increase year-over-year.
- Bellicum Pharmaceuticals, Inc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending September 30, 2023 was -$22.4M, a 37.7% decline year-over-year.
- Bellicum Pharmaceuticals, Inc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$25M, a 158% decline from 2021.
- Bellicum Pharmaceuticals, Inc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$9.7M, a 25.5% decline from 2020.
- Bellicum Pharmaceuticals, Inc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2020 was -$7.73M, a 93.1% increase from 2019.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Growth (%)